1Ielinska E, Niewiarowski W, Bodalski J, et al. Genotyping of the arylamine N-acetyltransferase polymorphism in the prediction of idiosyncratic reactions to trimethoprim-sulfamethoxazole in infants. Pharm World Sci, 1998,20:123-130.
2Bell DA, Taylor JA, Butler MA, et al. Genotype/phenotype discordance for human arylamine N-acetyltransferase reveals a new slow-acetylator allele common in African-Americans, Carcinogenesis, 1993,14:1689-1692.
3Gunnarsson I, Kanerud L, Pettersson E, et al. Predisposing factors in sulphasalazine-induced systemic lupus erythematosus.Br J Rheumatol, 1997,36: 1089-1094.
4Pawlik A, Ostanek L, Brzosko 1, et al. Increased genotype frequency of N-acetyltransferase 2 slow acetylation in patients with rheumatoid arthritis. Clin Pharmacol Ther, 2002,72: 319-325.
5Najim RA, Sharquie KE, A1-Janabi MH. Acetylator phenotype in Behcet's disease. AdvExp Med Biol, 2003,528: 131-138.
6Nyberg F, Hou SM, Hemminki K, et al. Glutathione Stransferase M1 and N-acetyhransferase 2 genetic polymor phisms and exposure to tobacco smoke in nonsmoking and smoking lung cancer patients and population controls, Cancer Epidemiol Biomark Prev, 1998, 7: 875-883.
7Zhou W, Liu G, Thurston S W, et al, Genetic polymorphisms in N-acetyltransferase-2 and microsomal epoxide hydrolase,cumulative cigarette smoking, and lung cancer, Cancer Epi demiol Biomarkers Prev, 2002, 11(1): 15-21.
8Seow A, Zhao B, Poh WT, et al, NAT-2 slow acetylator genotype is associated with increased risk of lung cancer among non-smoking Chinese women in Singapore Carcinogenesis, 1999,20(9): 1877-1881.
9Hou S M, Rybera D, Falt S, et al. GSTM1 and NAT-2 polymorphisms in operable and non-operable lung cancer patients.Carcinogenesis, 2000, 21(1): 49-54.
10Bouchardy C, Mitrunen K, Wikman H, et al. N-acetytransferase NAT1 and NAT-2 genotypes and lung cancer risk,Pharmacogenetics, 1998,8(4): 291-298.
二级参考文献5
1[1]Hein DW. N-acetyltransferase genetics and their role in predisposition to aromatic and heterocyclic amine-induced carcinogenesis [J]. Toxicol Lett, 2000;15(112-113):349-356.
2[2]Hein DW, Doll MA, Fretland AJ, et al. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms [J]. Cancer Epidemiol Biomarkers Prev, 2000; 9(1):29-42.
3[3]Varim G, Monteiro E, Silva R, et al. Polymorphisms of arylamine N-acetyltransferase (NAT1 and NAT2) and larynx cancer susceptibility [J]. ORL J Otorhinolaryngol Relat Spec, 2002; 64(3): 206-212.
4[5]Tiemersma EW, Kampmam E, Bueno de Mesquita HB, et al. Meat consumption, cigarette smoking, and genetic susceptibility in the etiology of colorectal cancer: Results from a dutch prospective study [J]. Cancer Causes Contr, 2002; 13(4): 383-393.
5[6]Fretland AJ, Leff MA, Doll MA, et al. Functional characterization of human N-acetyltransferase 2 (NAT2) single nucleotide polymorphisms [J]. Pharmacogenetics, 2001; 11(3): 207-215.
